BDX in “GLP-1 Eats Everything”
Becton, Dickinson and Company
Higher use of injectable obesity medicines expands the addressable market for pen needles and other drug-delivery components.
BDX impact map — “GLP-1 Eats Everything”
How this story travels from the headline to BDX’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading BDX impact map…
Price history, marked with story events
Jul 16, 2026 – Oct 16, 2026 · 60 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BULL side — Higher use of injectable obesity medicines expands the addressable market for pen needles and other drug-delivery components.
Read the full GLP-1 Eats Everything storyBull side
2 stories- Viewing
BDX in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Higher use of injectable obesity medicines expands the addressable market for pen needles and other drug-delivery components.
- Managed Care's Margin Machine Breaks
BDX in “Managed Care's Margin Machine Breaks”
FadingExposure: not rated yetRising utilization, tougher reimbursement and scrutiny of denials are shifting economics from insurers back to care providers.
Rising hospital admissions and treatment intensity increase consumption of its needles, catheters, medication-management products and laboratory supplies.
Bear side
0 storiesNo bear-side stories for BDX yet.